Hepatitis B virus reactivation with rituximab-containing regimen

Area of Science:

• Immunology
• Hepatology
• Oncology

Background:

• Rituximab is a monoclonal antibody used for B-cell non-Hodgkin's lymphoma and autoimmune conditions.
• Hepatitis B virus (HBV) reactivation is a serious complication of rituximab therapy.
• Preventing HBV reactivation is crucial for patient safety during rituximab treatment.

Purpose of the Study:

• To review current knowledge on rituximab-induced HBV reactivation.
• To discuss case analyses and identify remaining issues in prevention strategies.
• To provide insights into managing HBV risk in patients receiving rituximab.

Main Methods:

• Literature review of case analyses from multiple institutions.
• Synthesis of existing data on rituximab use and HBV reactivation.
• Analysis of current prevention strategies and their effectiveness.

Main Results:

• Rituximab is associated with significant risk of HBV reactivation across various indications.
• Case studies highlight the spectrum of HBV reactivation presentations.
• Current knowledge on prevention is rapidly evolving, with ongoing research.

Conclusions:

• Effective management of HBV reactivation risk is essential for patients on rituximab.
• Further research is needed to optimize preventative measures and treatment protocols.
• Close monitoring and prophylactic strategies are key to mitigating HBV reactivation.